Vertex, Arbor Biotechnologies extend agreement on precision gene editing technology
vchal



Vertex Pharmaceuticals (NASDAQ:VRTX) and Arbor Biotechnologies have extended a collaboration agreement that will provide the former with rights to the latter's novel precision editing technology for up to three diseases.
Terms call for Arbor to potentially receive milestone payments, as well as tiered royalties on sales of any products developed from the collaboration.

Arbor said that it is focused on discovering new technologies that enable gene knockout, reverse transcriptase editing, precise excisions, and large insertions into endogenous loci (locations within the genome).
The two companies began their partnership on gene-editing therapies in 2018.
Read why Seeking Alpha contributor Terry Chrisomalis calls Vertex (VRTX) a strong buy.